Brentuximab vedotin: Phase II started

Seattle Genetics began an open-label, U.S. Phase II trial (SGN35-006) to evaluate 1.8 mg/kg IV brentuximab vedotin given every 3 weeks in up to 50 relapsed patients who previously achieved a complete ...